JP2023511443A5 - - Google Patents
Info
- Publication number
- JP2023511443A5 JP2023511443A5 JP2022544775A JP2022544775A JP2023511443A5 JP 2023511443 A5 JP2023511443 A5 JP 2023511443A5 JP 2022544775 A JP2022544775 A JP 2022544775A JP 2022544775 A JP2022544775 A JP 2022544775A JP 2023511443 A5 JP2023511443 A5 JP 2023511443A5
- Authority
- JP
- Japan
- Prior art keywords
- active substance
- cells
- genetically modified
- mammal
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062965593P | 2020-01-24 | 2020-01-24 | |
| US62/965,593 | 2020-01-24 | ||
| PCT/US2021/014811 WO2021151038A1 (en) | 2020-01-24 | 2021-01-23 | Quantitative control of activity of engineered cells expressing universal immune receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511443A JP2023511443A (ja) | 2023-03-17 |
| JP2023511443A5 true JP2023511443A5 (https=) | 2024-01-30 |
Family
ID=76991850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544775A Pending JP2023511443A (ja) | 2020-01-24 | 2021-01-23 | 普遍的免疫受容体を発現する操作された細胞の活性の量的制御 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230103327A1 (https=) |
| EP (1) | EP4093412A4 (https=) |
| JP (1) | JP2023511443A (https=) |
| KR (1) | KR20220132577A (https=) |
| CN (1) | CN115397439A (https=) |
| AU (1) | AU2021209950A1 (https=) |
| BR (1) | BR112022014540A2 (https=) |
| CA (1) | CA3168878A1 (https=) |
| IL (1) | IL295036A (https=) |
| MX (1) | MX2022009146A (https=) |
| WO (1) | WO2021151038A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL310386A (en) * | 2021-07-28 | 2024-03-01 | Prescient Therapeutics Ltd | Universal receptor immune cell therapy |
| GB202306808D0 (en) * | 2023-05-09 | 2023-06-21 | Univ Oxford Innovation Ltd | Method for detecting interactions |
| WO2024241208A1 (ko) * | 2023-05-19 | 2024-11-28 | 서울대학교산학협력단 | Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016126608A1 (en) * | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3262063B1 (en) * | 2015-02-26 | 2021-09-22 | Var2 Pharmaceuticals ApS | Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems |
| US11377481B2 (en) * | 2015-12-22 | 2022-07-05 | The Trustees Of The University Of Pennsylvania | SpyCatcher and SpyTag: universal immune receptors for T cells |
-
2021
- 2021-01-23 CN CN202180023901.0A patent/CN115397439A/zh active Pending
- 2021-01-23 US US17/794,571 patent/US20230103327A1/en active Pending
- 2021-01-23 KR KR1020227029186A patent/KR20220132577A/ko active Pending
- 2021-01-23 CA CA3168878A patent/CA3168878A1/en active Pending
- 2021-01-23 JP JP2022544775A patent/JP2023511443A/ja active Pending
- 2021-01-23 MX MX2022009146A patent/MX2022009146A/es unknown
- 2021-01-23 AU AU2021209950A patent/AU2021209950A1/en active Pending
- 2021-01-23 IL IL295036A patent/IL295036A/en unknown
- 2021-01-23 EP EP21744299.5A patent/EP4093412A4/en active Pending
- 2021-01-23 WO PCT/US2021/014811 patent/WO2021151038A1/en not_active Ceased
- 2021-01-23 BR BR112022014540A patent/BR112022014540A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11932700B2 (en) | Use of chimeric antigen receptor modified cells to treat cancer | |
| Kochenderfer et al. | Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors | |
| Bartkowiak et al. | 4-1BB agonists: multi-potent potentiators of tumor immunity | |
| Eshhar | Tumor-specific T-bodies: towards clinical application | |
| Murata et al. | OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen | |
| Batlevi et al. | Novel immunotherapies in lymphoid malignancies | |
| Cayabyab et al. | CD40 preferentially costimulates activation of CD4+ T lymphocytes. | |
| JP2022166133A (ja) | 免疫療法のためのナノ粒子組成物及び方法 | |
| JP2023511443A5 (https=) | ||
| WO2021007428A2 (en) | Molecules, compositions and methods for treatment of cancer | |
| IL293220B2 (en) | Compositions and methods for antibodies and fusion proteins targeting immune modulation | |
| JP2025183279A (ja) | Ｂｃｍａを標的とする操作された免疫細胞及びその使用 | |
| AU2003225431B2 (en) | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 | |
| JP2021513859A (ja) | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 | |
| JP2010047591A (ja) | ヒト癌を処置するのに有用なキメライムノレセプター | |
| US20120027759A1 (en) | Methods of enhancing t cell responsiveness | |
| KR20230095083A (ko) | Cd7 표적의 키메라 항원 수용체 및 이의 용도 | |
| US20210095029A1 (en) | Compositions and methods for treating cancer | |
| Jung et al. | Immunotherapy for the treatment of multiple myeloma | |
| US20240425579A1 (en) | Compositions and methods that inhibit il-23 signaling | |
| JP2009530361A (ja) | 免疫細胞刺激のための可逆的に阻害された抗体 | |
| CN102036677A (zh) | 热休克蛋白gp96的疫苗接种及其使用方法 | |
| D'Arrigo et al. | Manipulation of the immune system for cancer defeat: a focus on the T cell inhibitory checkpoint molecules | |
| JP7271037B2 (ja) | 免疫シナプスを安定化させるキメラ抗原受容体（ｃａｒ）ｔ細胞 | |
| JP2023505067A (ja) | Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質および免疫チェックポイント抑制剤を含む癌治療用医薬組成物 |